TABLE 2.
The treatment characteristics of patients
| Treatment characteristics | Patients n (%) (n = 172) |
|---|---|
| Previous anti‐HER2 treatment | |
| Neoadjuvant setting | 10 (5.8) |
| Adjuvant setting | 48 (27.9) |
| Metastatic setting | 137 (79.7) |
| No | 4 (2.3) |
| Prior HER2‐targeted therapy | |
| Trastuzumab | 164 (95.3) |
| Pertuzumab | 3 (1.7) |
| Lapatinib | 44 (25.6) |
| T‐DM1 | 2 (1.2) |
| Other | 4 (2.3) |
| Resistant to trastuzumab therapy | |
| Resistance | 50 (29.1) |
| Refractoriness | 92 (53.5) |
| No | 30 (17.4) |
| Treatment lines for pyrotinib at metastatic setting | |
| 1 | 28 (16.3) |
| 2 | 62 (36.0) |
| ≥3 | 82 (47.7) |
| Initial dose of pyrotinib (mg) | |
| 400 | 170 (98.8) |
| 320 | 1 (0.6) |
| 240 | 1 (0.6) |
| Dose adjustment of pyrotinib (mg) | |
| 400 → 320 | 12 (7.0) |
| 400 → 320 → 240 | 1 (0.6) |
| 400 → 240 | 1 (0.6) |
| 400 → 240 → 400 | 1 (0.6) |
| Treatment interruption | |
| Due to AEs | 3 (1.7) |
| Other | 1 (0.6) |
| Pyrotinib treatment regimen | |
| Pyrotinib alone | 16 (9.3) |
| Pyrotinib + trastuzumab + chemotherapy | 9 (5.2) |
| Pyrotinib + trastuzumab + vinorelbine | 2 (1.2) |
| Pyrotinib + trastuzumab + capecitabine | 4 (2.3) |
| Pyrotinib + trastuzumab + taxane | 3 (1.7) |
| Pyrotinib + chemotherapy | 133 (77.3) |
| Pyrotinib + taxane | 19 (11.0) |
| Pyrotinib + capecitabine | 70 (40.7) |
| Pyrotinib + vinorelbine | 28 (16.3) |
| Pyrotinib + gemcitabine | 9 (5.2) |
| Pyrotinib + other | 7 (4.1) |
| Pyrotinib + endocrinotherapy | 14 (8.1) |